PLN and cardiac sarcoidosis: Patients who had received a CRT‐D were then excluded (n = 123), as were those with HCM (n = 28), ARVC (n = 6), cardiac sarcoidosis (n = 3), cardiac amyloidosis (n = 5), Brugada syndrome (n = 1), and specific genetic variants associated with an increased SCD risk, including the PLN p.Arg14del mutation (n = 3), LMNA mutation (n = 1), and pathogenic DSP mutation (n = 1) (Fig. 3).